Merck's $1.35B Merger With Biotech Faces Investor Suits
Imago Biosciences got hit with three investor actions in as many days this week, alleging it sent out solicitation statements with missing financial information to shareholders evaluating tender offers they received...To view the full article, register now.
Already a subscriber? Click here to view full article